TriangleNCT00295880 · STUDY IN CONTEXT
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Number of days to neutrophil recovery observed in recipients of two umbilical cord blood units (UCB)administered i.v. Neutrophil recovery is defined as first of 3 consecutive days with ANC (absolute neutrophil count) greater than or equal to 500/ul.
Number of patients with sustained neutrophil recovery with chimerism (evidence of engraftment of both cord blood transplants) at 6 months.
Number of patients who received both cord blood units and achieved sustained donor engraftment
Number of patients who exhibited grade II-IV acute GVHD at 100 days post umbilical cord blood transplant.
Number of patients who were deceased at days 100 and 180 from any cause other than relapse.
Overall survival of patients-Number of patients who were alive at Day 100 and 1 year post transplant.
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- trial label
- Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 6
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0000
- source section id
- NCT00295880-om-0000
- source outcome index
- 0
- endpoint
- Median Number of Days to Neutrophil Engraftment
- endpoint definition
- Number of days to neutrophil recovery observed in recipients of two umbilical cord blood units (UCB)administered i.v. Neutrophil recovery is defined as first of 3 consecutive days with ANC (absolute neutrophil count) greater than or equal to 500/ul.
- time origin
- Daily through Day 60 post transplant
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0001
- source section id
- NCT00295880-om-0001
- source outcome index
- 1
- endpoint
- Number of Patients Achieving Neutrophil Recovery
- endpoint definition
- Number of patients with sustained neutrophil recovery with chimerism (evidence of engraftment of both cord blood transplants) at 6 months.
- time origin
- 6 months
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Patients who completed treatment.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0002
- source section id
- NCT00295880-om-0002
- source outcome index
- 2
- endpoint
- Number of Patients With Evidence of Engraftment.
- endpoint definition
- Number of patients who received both cord blood units and achieved sustained donor engraftment
- time origin
- 1 year
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- 1 patient was not evaluable due to graft failure
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0003
- source section id
- NCT00295880-om-0003
- source outcome index
- 3
- endpoint
- Number of Patients With Acute Graft-versus-host Disease (GVHD)
- endpoint definition
- Number of patients who exhibited grade II-IV acute GVHD at 100 days post umbilical cord blood transplant.
- time origin
- 100 days post transplant
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- 2 patients were not graded for acute GVHD due to graft failure.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0004
- source section id
- NCT00295880-om-0004
- source outcome index
- 4
- endpoint
- Number of Patients With Transplant-related Mortality (TRM)
- endpoint definition
- Number of patients who were deceased at days 100 and 180 from any cause other than relapse.
- time origin
- Day 100 and Day 180
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0005
- source section id
- NCT00295880-om-0005
- source outcome index
- 5
- endpoint
- Number of Patients Surviving at Day 100 and 1 Year.
- endpoint definition
- Overall survival of patients-Number of patients who were alive at Day 100 and 1 year post transplant.
- time origin
- Day 100 and 1 year
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Umbilical Cord Blood Transplant Patients
- regimen
- Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00295880-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0001
- arm key
- OG000
- arm label
- Umbilical Cord Blood Transplant Patients
- regimen
- Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00295880-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0002
- arm key
- OG000
- arm label
- Umbilical Cord Blood Transplant Patients
- regimen
- Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00295880-om-0002#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0003
- arm key
- OG000
- arm label
- Umbilical Cord Blood Transplant Patients
- regimen
- Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.
- analyzed count
- 8
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00295880-om-0003#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0004
- arm key
- OG000
- arm label
- Umbilical Cord Blood Transplant Patients
- regimen
- Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00295880-om-0004#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- outcome key
- om-0005
- arm key
- OG000
- arm label
- Umbilical Cord Blood Transplant Patients
- regimen
- Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00295880-om-0005#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00295880
- harm key
- EG000
- source section id
- NCT00295880-ae
- event group key
- EG000
- event group label
- Umbilical Cord Blood Transplant Patients
- serious affected
- 5
- serious at risk
- 12
- other affected
- 0
- other at risk
- 12
- frequency threshold
- 5
- collection period
- Source null
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice